Sirona Medical Raises $40M Series D as Platform Usage Triples
Round led by Avidity Partners. Platform usage, ARR, & contracted ARR all grew by more than 2.5x year-over-year.…
New composite outcomes data show patients treated with Lilly’s Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn’s disease at one year
In LUCENT-2, more than one in four (27.7%) Omvoh-treated patients with ulcerative colitis achieved comprehensive disease control, a…
Lilly’s triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes
In TRIUMPH-2, participants with obesity and type 2 diabetes taking retatrutide 12 mg lost an average of 49.6…
Oracle and Buck Institute for Research on Aging Advance Landmark Federal Aging Research Initiative
Buck Institute aims to advance bioinformatics using Oracle Life Sciences Data Intelligence to transform aging research into a…
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
Designation is driven by compelling Phase 2 clinical data in patients with complicated Staphylococcus aureus bacteremia showing AP-SA02…
Parker Waichman Applauds Health Canada and Australia for Strengthening NAION Safety Guidance for Certain GLP-1 Medications
Canada now directs physicians to urgently evaluate sudden vision loss and discontinue Ozempic and Mounjaro if NAION is…
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
AtaiBeckley’s lead program, BPL-003, is designed to provide durable relief from treatment-resistant depression Acquisition expands Lilly’s neuroscience pipeline…
Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada
Mississauga, ON, July 15, 2026 /PRNewswire/ – Septa Pharmaceuticals Inc., a rapidly growing leader in the Canadian healthcare…
Machine Learning Model Accurately Predicts Long-Term Risk of Type 2 Diabetes
Study of Over Three Million Patients for Risk of Type 2 Diabetes Demonstrates Potential for More Advanced Approach…
Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlite™ in Landmark CREDENCE Trial
New analysis supports DNlite™ for earlier renal risk stratification in patients with type 2 diabetes and chronic kidney…
First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control
Phase 2 Study Results Highlight Use of Once-Daily Injection for Weight Loss and Reduction in Insulin Use NEW…
Novo Nordisk Introduces Extra Savings for Canadians Who Choose Ozempic®
MISSISSAUGA, ON, May 26, 2026 /CNW/ – Novo Nordisk Canada is announcing that effective Friday, May 29, 2026,…